Instil Bio, Inc. Files 8-K on Shareholder Votes

Ticker: TIL · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1789769

Instil Bio, INC. 8-K Filing Summary
FieldDetail
CompanyInstil Bio, INC. (TIL)
Form Type8-K
Filed DateJun 17, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.000001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, sec-filing

Related Tickers: TIL

TL;DR

Instil Bio (TIL) filed an 8-K on shareholder votes - check for governance updates.

AI Summary

Instil Bio, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the company's corporate information, including its principal executive offices in Dallas, Texas.

Why It Matters

This filing indicates that Instil Bio, Inc. held or is reporting on a shareholder vote, which could pertain to significant corporate decisions or governance matters.

Risk Assessment

Risk Level: low — This is a routine corporate filing reporting on shareholder votes, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Instil Bio, Inc.'s security holders?

The filing does not specify the exact matters voted upon, only that Item 5.07 (Submission of Matters to a Vote of Security Holders) is being reported.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 13, 2024.

What is Instil Bio, Inc.'s principal executive office address?

The principal executive offices are located at 3963 Maple Avenue, Suite 350, Dallas, Texas 75219.

What is the Commission File Number for Instil Bio, Inc.?

The Commission File Number for Instil Bio, Inc. is 001-40215.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-17 17:02:09

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Instil Bio, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024. Of the 6,503,913 shares of the Company's common stock outstanding as of the record date, 5,737,089 shares, or approximately 88.20% were present or represented by proxy at the Annual Meeting. The following is a brief description of each matter voted upon and the certified results. Proposal 1. Stockholders elected each of the following nominees to serve as Class III directors on the Company's board of directors until the Company's 2027 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified. The voting results for such nominees were as follows: Director Name Votes For Votes Withheld Broker Non- Votes R. Kent McGaughy, Jr. 4,499,758 129,194 1,108,137 Dr. Gwendolyn Binder 4,351,989 276,963 1,108,137 Proposal 2. Stockholders ratified the selection by Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 5,718,919 11,543 6,627 —

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Date: June 17, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing